Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Azetukalner SCHEMBL30429530 | 1.00 | KCNQ2 (1.00) | KCNQ2KCNQ3 | |
| SCHEMBL1001177 | 0.96 | KCNQ2 (0.92) | KCNQ2KCNQ3 | |
| SCHEMBL30796106 | 0.96 | KCNQ2 (0.92) | KCNQ2KCNQ3 | |
| Azetukalner SCHEMBL31441336 | 0.94 | KCNQ2 (0.89) | KCNQ2KCNQ3 | |
| SCHEMBL25101365 | 0.94 | KCNQ2 (0.89) | KCNQ2KCNQ3 | |
| SCHEMBL30814177 | 0.93 | KCNQ2 (0.87) | KCNQ2KCNQ3 | |
| SCHEMBL1003007 | 0.93 | KCNQ2 (0.87) | KCNQ2KCNQ3 | |
| Azetukalner SCHEMBL31441324 | 0.93 | KCNQ2 (0.87) | KCNQ2KCNQ3 | |
| SCHEMBL25286333 | 0.92 | KCNQ2 (0.84) | KCNQ2KCNQ3 | |
| SCHEMBL25244230 | 0.91 | KCNQ2 (0.82) | KCNQ2KCNQ3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 168 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250275957-A1 | METHODS FOR ENHANCING THE BIOAVAILABILITY AND EXPOSURE OF A VOLTAGE-GATED POTASSIUM CHANNEL OPENER | XENON PHARMACEUTICALS INC. (CA) | 2025-09-04 | — | — | US | claimed |
| US-20250221980-A1 | METHODS FOR ENHANCING THE BIOAVAILABILITY AND EXPOSURE OF A VOLTAGE-GATED POTASSIUM CHANNEL OPENER | XENON PHARMACEUTICALS INC. (CA) | 2025-07-10 | — | — | US | claimed |
| US-20250186426-A1 | METHODS AND USES FOR TREATING ANHEDONIA | XENON PHARMACEUTICALS INC. (CA) | 2025-06-12 | — | — | US | claimed |
| US-12319657-B1 | Solid state crystalline forms of a selective potassium channel modulator | XENON PHARMACEUTICALS INC. (CA) | 2025-06-03 | — | — | US | claimed |
| US-20250108044-A1 | METHODS OF TREATING DEPRESSIVE DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2025-04-03 | — | — | US | claimed |
| US-12178811-B2 | Methods of treating depressive disorders | XENON PHARMACEUTICALS INC. (CA) | 2024-12-31 | — | — | US | claimed |
| US-12171759-B1 | Methods and uses for treating anhedonia | XENON PHARMACEUTICALS INC. (CA) | 2024-12-24 | — | — | US | claimed |
| US-20240408076-A1 | METHODS AND USES FOR TREATING ANHEDONIA | XENON PHARMACEUTICALS INC. (CA) | 2024-12-12 | — | — | US | claimed |
| US-20240408075-A1 | CONJOINT THERAPY FOR TREATING SEIZURE DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2024-12-12 | — | — | US | claimed |
| EP-4041713-B1 | SOLID STATE CRYSTALLINE FORMS OF A SELECTIVE POTASSIUM CHANNEL MODULATOR | XENON PHARMACEUTICALS INC (CA) | 2024-12-11 | — | — | EP | claimed |
| US-20210213009-A1 | METHODS OF TREATING PAIN | XENON PHARMACEUTICALS INC. (CA) | 2021-07-15 | — | — | US | claimed |
| US-20210161886-A1 | METHODS OF TREATING DEPRESSIVE DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2021-06-03 | — | — | US | claimed |
| US-20210147363-A1 | SOLID STATE CRYSTALLINE FORMS OF A SELECTIVE POTASSIUM CHANNEL MODULATOR | XENON PHARMACEUTICALS INC. (CA) | 2021-05-20 | — | — | US | claimed |
| EP-3790548-A1 | METHODS FOR ENHANCING THE BIOAVAILABILITY AND EXPOSURE OF A VOLTAGE-GATED POTASSIUM CHANNEL OPENER | Xenon Pharmaceuticals Inc. (CA) | 2021-03-17 | — | — | EP | claimed |
| CN-112384216-A | Methods for enhancing bioavailability and voltage-gated potassium ion channel open exposure | 泽农医药公司 | 2021-02-19 | — | — | CN | claimed |
| US-20190343823-A1 | METHODS FOR ENHANCING THE BIOAVAILABILITY AND EXPOSURE OF A VOLTAGE-GATED POTASSIUM CHANNEL OPENER | XENON PHARMACEUTICALS INC. (CA) | 2019-11-14 | — | — | US | claimed |
| WO-2019217924-A1 | METHODS FOR ENHANCING THE BIOAVAILABILITY AND EXPOSURE OF A VOLTAGE-GATED POTASSIUM CHANNEL OPENER | XENON PHARMACEUTICALS INC. (CA) | 2019-11-14 | — | — | WO | claimed |
| EP-2061465-B1 | DERIVATIVES OF 4-(N-AZACYCLOALKYL) ANILIDES AS POTASSIUM CHANNEL MODULATORS | VALEANT PHARMACEUTICALS INT (US) | 2013-04-10 | — | — | EP | claimed |
| US-8293911-B2 | Seizure disorders; antiepileptic agents; N-(2-chloro-4-(3,4-dihydroisoquinolin-2(1H)-yl)-6-(trifluoromethyl)phenyl)-3,3-dimethylbutanamide for example | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2012-10-23 | — | — | US | claimed |
| US-20080139610-A1 | Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators | VALEANT PHARMACEUTICALS NORTH AMERICA (US) | 2008-06-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12171759-B1 | Methods and uses for treating anhedonia | CHAT, HNMT, PNMT | KCNQ2 306/4885KCNQ3 221/4885 |
| US-20080139610-A1 | Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators | KCNQ2, KCNQ1, KCNQ5 | KCNQ2 1/4885KCNQ3 6/4885 |
| US-20250186426-A1 | METHODS AND USES FOR TREATING ANHEDONIA | CHAT, HNMT, PNMT | KCNQ2 306/4885KCNQ3 221/4885 |
| US-20250275957-A1 | METHODS FOR ENHANCING THE BIOAVAILABILITY AND EXPOSURE OF A VOLTAGE-GATED POTASSIUM CHANNEL OPENER | KCNN3, KCNAB1, KCNQ2 | KCNQ2 3/4885KCNQ3 7/4885 |
| US-20250108044-A1 | METHODS OF TREATING DEPRESSIVE DISORDERS | HTR2A, PNMT, HTR3B | KCNQ2 212/4885KCNQ3 123/4885 |
| US-20240408075-A1 | CONJOINT THERAPY FOR TREATING SEIZURE DISORDERS | SMPD4, PNMT, NPY4R | KCNQ2 30/4885KCNQ3 17/4885 |
| US-20210147363-A1 | SOLID STATE CRYSTALLINE FORMS OF A SELECTIVE POTASSIUM CHANNEL MODULATOR | KCNQ2, KCNN2, KCNN3 | KCNQ2 1/4885KCNQ3 9/4885 |
| US-12178811-B2 | Methods of treating depressive disorders | HTR2A, PNMT, HTR3B | KCNQ2 212/4885KCNQ3 123/4885 |
| US-20210213009-A1 | METHODS OF TREATING PAIN | ACHE, OPRL1, METTL3 | KCNQ2 198/4885KCNQ3 61/4885 |
| US-20240408076-A1 | METHODS AND USES FOR TREATING ANHEDONIA | CHAT, HNMT, PNMT | KCNQ2 306/4885KCNQ3 221/4885 |
| US-20250221980-A1 | METHODS FOR ENHANCING THE BIOAVAILABILITY AND EXPOSURE OF A VOLTAGE-GATED POTASSIUM CHANNEL OPENER | KCNN3, KCNAB1, KCNQ2 | KCNQ2 3/4885KCNQ3 7/4885 |
| US-20190343823-A1 | METHODS FOR ENHANCING THE BIOAVAILABILITY AND EXPOSURE OF A VOLTAGE-GATED POTASSIUM CHANNEL OPENER | KCNN3, KCNAB1, KCNQ2 | KCNQ2 3/4885KCNQ3 7/4885 |
| US-12319657-B1 | Solid state crystalline forms of a selective potassium channel modulator | KCNQ2, KCNN2, KCNN3 | KCNQ2 1/4885KCNQ3 9/4885 |
| US-20210161886-A1 | METHODS OF TREATING DEPRESSIVE DISORDERS | HTR2A, PNMT, HTR3B | KCNQ2 212/4885KCNQ3 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.